Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder

Overview

Journal Basic Clin Pharmacol Toxicol

Date 2025 Feb 1

PMID 39891507

Authors

Mette Kruse Klausen

Gitte Moos Knudsen

Tina Vilsboll

Anders Fink-Jensen

Affiliations

Soon will be listed here.

Abstract

In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. GLP-1 is a naturally occurring peptide produced in the small intestines and the brain, regulating plasma glucose levels and satiety. This focused review will report on the preclinical studies, case stories, register-based cohort studies, brain-imaging data and secondary analysis of clinical data supporting the role of GLP-1RAs as a novel treatment of AUD. Several clinical trials are ongoing, examining the potential effects of the GLP-1RA semaglutide in AUD.

References

Wium-Andersen I, Wium-Andersen M, Fink-Jensen A, Rungby J, Jorgensen M, Osler M . Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. Basic Clin Pharmacol Toxicol. 2022; 131(5):372-379. DOI: 10.1111/bcpt.13776. View

Farokhnia M, Browning B, Crozier M, Sun H, Akhlaghi F, Leggio L . The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study. Addict Biol. 2022; 27(5):e13211. DOI: 10.1111/adb.13211. View

Mahalingam S, Bellamkonda R, Arumugam M, Perumal S, Yoon J, Casey C . Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease. Biochem Pharmacol. 2023; 213:115613. PMC: 10351880. DOI: 10.1016/j.bcp.2023.115613. View

Conte C, Hall K, Klein S . Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?. JAMA. 2024; 332(1):9-10. DOI: 10.1001/jama.2024.6586. View

Chuong V, Farokhnia M, Khom S, Pince C, Elvig S, Vlkolinsky R . The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023; 8(12). PMC: 10371247. DOI: 10.1172/jci.insight.170671. View

Sirohi S, Schurdak J, Seeley R, Benoit S, Davis J . Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol Behav. 2016; 161:140-144. DOI: 10.1016/j.physbeh.2016.04.013. View

Egecioglu E, Engel J, Jerlhag E . The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 2013; 8(10):e77284. PMC: 3799694. DOI: 10.1371/journal.pone.0077284. View

Shen W . Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacol Rep. 2018; 38(3):105-116. PMC: 7292332. DOI: 10.1002/npr2.12028. View

Anderson S, Beutel T, Trujillo J . Oral semaglutide in type 2 diabetes. J Diabetes Complications. 2020; 34(4):107520. DOI: 10.1016/j.jdiacomp.2019.107520. View

10.

Kohn R, Saxena S, Levav I, Saraceno B . The treatment gap in mental health care. Bull World Health Organ. 2005; 82(11):858-66. PMC: 2623050. DOI: /S0042-96862004001100011. View

11.

Wang W, Volkow N, Berger N, Davis P, Kaelber D, Xu R . Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024; 15(1):4548. PMC: 11133479. DOI: 10.1038/s41467-024-48780-6. View

12.

Lanng A, Gasbjerg L, Bergmann N, Bergmann S, Helsted M, Gillum M . Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocr Connect. 2019; 8(10):1372-1382. PMC: 6790903. DOI: 10.1530/EC-19-0317. View

13.

Ostlund M, Backman O, Marsk R, Stockeld D, Lagergren J, Rasmussen F . Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery. JAMA Surg. 2013; 148(4):374-7. DOI: 10.1001/jamasurg.2013.700. View

14.

Johnson B, Ait-Daoud N, Bowden C, DiClemente C, Roache J, Lawson K . Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003; 361(9370):1677-85. DOI: 10.1016/S0140-6736(03)13370-3. View

15.

Dalgaard M, Thomsen C, Rasmussen B, Holst J, Hermansen K . Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients. Metabolism. 2003; 53(1):77-83. DOI: 10.1016/j.metabol.2003.08.011. View

16.

Carvalho A, Heilig M, Perez A, Probst C, Rehm J . Alcohol use disorders. Lancet. 2019; 394(10200):781-792. DOI: 10.1016/S0140-6736(19)31775-1. View

16.

Kret M, De Dreu C . Oxytocin-Motivated Ally Selection is Moderated by Fetal Testosterone Exposure and Empathic Concern. Front Neurosci. 2013; 7:1. PMC: 3558663. DOI: 10.3389/fnins.2013.00001. View

17.

Askgaard G, Leon D, Deleuran T, Tolstrup J . Hospital admissions and mortality in the 15 years after a first-time hospital contact with an alcohol problem: a prospective cohort study using the entire Danish population. Int J Epidemiol. 2019; 49(1):94-102. DOI: 10.1093/ije/dyz159. View

18.

Bramming M, Becker U, Jorgensen M, Neermark S, Bisgaard T, Tolstrup J . Bariatric surgery and risk of alcohol use disorder: a register-based cohort study. Int J Epidemiol. 2020; 49(6):1826-1835. DOI: 10.1093/ije/dyaa147. View

19.

Abraham K, Kearney M, Reynolds L, Thyfault J . Red wine enhances glucose-dependent insulinotropic peptide (GIP) and insulin responses in type 2 diabetes during an oral glucose tolerance test. Diabetol Int. 2019; 7(2):173-180. PMC: 6224998. DOI: 10.1007/s13340-015-0234-y. View